At the time of writing, Precision Biosciences Inc [DTIL] stock is trading at $4.94, up 1.65%. An important factor to consider is whether the stock is rising or falling in short-term value. The DTIL shares have gain 9.29% over the last week, with a monthly amount glided 9.05%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Precision Biosciences Inc [NASDAQ: DTIL] stock has seen the most recent analyst activity on January 10, 2025, when BMO Capital Markets upgraded its rating to a Outperform but kept the price target unchanged to $34 for it. Previously, Guggenheim started tracking the stock with Buy rating on April 30, 2024, and set its price target to $19. On June 17, 2022, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $7 on the stock. William Blair downgraded its rating to a Mkt Perform. Goldman downgraded its rating to Neutral for this stock on April 03, 2020, and downed its price target to $7. In a note dated March 05, 2020, Stifel initiated an Buy rating and provided a target price of $21 on this stock.
For the past year, the stock price of Precision Biosciences Inc fluctuated between $3.61 and $11.09. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Precision Biosciences Inc [NASDAQ: DTIL] shares were valued at $4.94 at the most recent close of the market. An investor can expect a potential return of 213.77% based on the average DTIL price forecast.
Analyzing the DTIL fundamentals
According to Precision Biosciences Inc [NASDAQ:DTIL], the company’s sales were 51.14M for trailing twelve months, which represents an -99.84% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.43%, and Net Profit Margin reading is -0.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.36 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.55 points at the first support level, and at 4.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.29, and for the 2nd resistance point, it is at 5.64.
Ratios To Look Out For
It is important to note that Precision Biosciences Inc [NASDAQ:DTIL] has a current ratio of 6.62. On the other hand, the Quick Ratio is 6.62, and the Cash Ratio is 6.23. Considering the valuation of this stock, the price to sales ratio is 1.07, the price to book ratio is 1.06.
Transactions by insiders
Recent insider trading involved Kelly John Alexander, Chief Financial Officer, that happened on Jul 03 ’25 when 14827.0 shares were sold. Officer, Kelly John Alexander completed a deal on Jul 03 ’25 to buy 14827.0 shares. Meanwhile, Director Brown Melinda bought 1682.0 shares on Jun 25 ’25.
